Neuropilin-1 is expressed by chronic lymphocytic leukemia B cells.
Neuropilin-1 is expressed by chronic lymphocytic leukemia B cells.
复制标题
Neuropilin-1 由慢性淋巴细胞白血病 B 细胞表达。
DOI：
10.1016/j.leukres.2008.02.020
复制
发表时间：
2008
影响因子：
2.7
通讯作者：
Kay,NeilE
中科院分区：
文献类型：
--
作者：
Nowakowski,GrzegorzS;Mukhopadhyay,Debabrata;Wu,Xiaosheng;Kay,NeilE
原代 CLL B 细胞已被证明可分泌血管内皮生长因子 (VEGF)，并且分泌的 VEGF 可通过被认为是自分泌环路增加白血病 CLL B 细胞对自发性和药物诱导的细胞凋亡的抵抗力 [1]。我们和其他人已经证明，CLL B 细胞表达 VEGF 受体 1 (VEGF-R1) 和 2 (VEGF-R2)，为这些细胞提供 VEGF 结合能力 [2]。虽然这些受体被证明在肿瘤细胞上表达，并且可能参与肿瘤模型中的自分泌存活和新血管形成，但越来越多的证据表明另一种 VEGF 受体神经毡蛋白-1 (NRP-1) 在这些肿瘤血管生成特征中至关重要，并且很可能参与 VEGF 介导的细胞凋亡抵抗 [3]。 NRP-1 的异常表达已在多种实体瘤和急性髓系白血病中显示出来。在后者中，NRP-1 表达与这些患者的总生存期缩短相关[4]。最近，我们研究了 CLL 和正常 B 细胞中的 NRP-1 表达。所有 CLL 患者均根据美国国家癌症研究所 (NCI) 工作组的定义进行了确诊。 Western blot 分析中使用的患者样本来自所有 Rai 阶段，通过流式细胞术评估，其中存在超过 90% 的 CD19+ 和 CD5+ CLL B 细胞。使用单克隆抗 NRP-1 抗体（Calbiochem，圣地亚哥，加利福尼亚州）对 10 名 CLL 患者进行蛋白质印迹，结果显示 10 名患者中有 7 名表达 NRP-1 蛋白（图 1A）。我们还通过流式细胞术评估了表面 NRP-1 表达 (n= 5)（图 1B）。该队列中的患者属于早期 Rai 阶段 (0–2)，具有不同程度的淋巴细胞增多（中位数，63,000× 109 L− 1；范围，6000–123,000）。分离的单核细胞用单克隆别藻蓝蛋白标记的抗 CD19 抗体（BD Biosciences，圣何塞，加利福尼亚州）和藻红蛋白标记的抗 NRP-1 抗体进行染色（Miltenyi Biotec，奥本，加利福尼亚州），然后通过流式细胞术门控 CD19+ 细胞进行分析。使用同种型特异性抗体作为对照。在五名患者中的两名中观察到 NRP-1 表达，但在从健康对照获得的三个正常 B 细胞中的三个中未检测到 NRP-1 表达。我们的结果首次证明，
Primary CLL B cells have been shown to secrete vascular endothelial growth factor (VEGF), and secreted VEGF was shown to increase the resistance of leukemic CLL B cells to spontaneous and drug induced apoptosis through what is believed to be an autocrine loop [1]. We and others have shown that CLL B cells express VEGF receptor 1 (VEGF-R1) and 2 (VEGF-R2) which provide these cells with a capacity for VEGF binding [2]. While these receptors were shown to be expressed on tumor cells and are likely to be involved in both autocrine survival as well as neovascularization in tumor models, there is increasing evidence that another VEGF receptor, neuropilin-1 (NRP-1), is critical in these tumor angiogenic features and most likely involved in VEGF mediated resistance to apoptosis [3]. Aberrant NRP-1 expression has been shown in several solid tumors and acute myeloid leukemia. In the latter, NRP-1 expression was associated with shortened overall survival of these patients [4]. Recently, we have investigated NRP-1 expression in CLL and normal B cells. All CLL patients had a confirmed diagnosis using the National Cancer Institute (NCI) Working Group definition. Patients’ samples utilized in Western blot analysis were from all Rai stages where more than 90% of CD19+ and CD5+ CLL B cells were present as assessed by flow cytometry. Western blot was performed for 10 CLL patients using monoclonal anti-NRP-1 antibodies (Calbiochem, San Diego, CA) and showed NRP-1 protein expression in 7 of 10 patients (Fig. 1A). We also evaluated surface NRP-1 expression by flow cytometry (n= 5)(Fig. 1B). Patients in this cohort were from early Rai stages (0–2) and had a varying degree of lymphocytosis (median, 63,000× 109 L− 1; range, 6000–123,000).Isolated mononuclear cells were stained with monoclonal allophycocyanin labeled anti-CD19 antibodies (BD Biosciences, San Jose, CA) and phycoerythrin labeled anti-NRP-1 antibodies (Miltenyi Biotec, Auburn, CA) and then analyzed by flow cytometry gating on CD19+ cells. Isotype-specific antibodies were used as controls. NRP-1 expression by flow was seen in two of five patients, but NRP-1 expression was not detected in three of three normal B cells obtained from healthy controls. Our results demonstrate, for the first time,
登录
查看更多内容
影响因子：
2.4
作者：
KLATT, DH
通讯作者：
KLATT, DH
一种分析持续发声中声音抖动的方法。
DOI：
--
发表时间：
1973
期刊：
影响因子：
--
作者：
H. Hollien;J. F. Michel;E. Thomas Doherty
通讯作者：
E. Thomas Doherty
食道扬声器产生的元音的声音粗糙度和抖动特征。
DOI：
--
发表时间：
1978
期刊：
Journal of Speech and Hearing Research
影响因子：
--
作者：
B. E. Smith;B. Weinberg;L. Feth;Y. Horii
通讯作者：
Y. Horii
病理声音的一些感知维度和声学相关性。
DOI：
--
发表时间：
1976
期刊：
Acta oto-laryngologica. Supplementum
影响因子：
--
作者：
H. Takahashi;Y. Koike
通讯作者：
Y. Koike
正常和病态声音中的音调扰动。
DOI：
--
发表时间：
1975
期刊：
影响因子：
--
作者：
K. Kitajima;M. Tanabe;N. Isshiki
通讯作者：
N. Isshiki